Download PDF
Horm Metab Res 2018; 50(06): 441-452
DOI: 10.1055/a-0623-2909
Review
© Georg Thieme Verlag KG Stuttgart · New York

An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity

Nasim Babaknejad
1   Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2   Department of Biology, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran
3   Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
,
Hashem Nayeri
3   Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
,
Roohullah Hemmati
2   Department of Biology, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran
,
Somaye Bahrami
3   Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
,
Ahmad Esmaillzadeh
4   Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
5   Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
6   Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
› Author Affiliations
Further Information

Publication History

received 06 January 2018

accepted 17 April 2018

Publication Date:
08 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Fibroblast growth factors (FGFs) are responsible for the regulation of a wide range of biological functions, among which cellular proliferation, survival, migration, and differentiation could be pointed out. FGF19 controls the enterohepatic bile acid/cholesterol system, and FGF21 modulates fatty acid/glucose metabolism. Obesity, type 2 diabetes, coronary artery disease, and cancer, all can alter FGF21 circulating concentrations. In contrast to FGF21, metabolic diseases exhibit reduced serum FGF19 levels. Accordingly, FGF19 and FGF21 play important roles in regulating glucose and lipid metabolism. Hence, we present here a timely review on the relationship between FGF19/21 and metabolic diseases, especially obesity, and their probable role in development and treatment of obesity seems necessary.

Key words

FGF21 - FGF19 - metabolic disorders - obesity
 

  • References

  • 1 Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Drug Discov 2009; 8: 235-253
    CrossrefPubMedGoogle Scholar
  • 2 Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-279
    CrossrefPubMedGoogle Scholar
  • 3 Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. J Hepatol 2012; 56: 2404-2411
    CrossrefPubMedGoogle Scholar
  • 4 Guan D, Zhao L, Chen D, Yu B, Yu J. Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state. J Transl Med 2016; 14: 016-0821
    CrossrefPubMedGoogle Scholar
  • 5 Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS, Mohammadi M. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-3428
    CrossrefPubMedGoogle Scholar
  • 6 Goetz R, Ohnishi M, Kir S, Kurosu H, Wang L, Pastor J, Ma J, Gai W, Kuro-o M, Razzaque MS, Mohammadi M. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 2012; 287: 29134-29146
    CrossrefPubMedGoogle Scholar
  • 7 Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012; 26: 312-324
    CrossrefPubMedGoogle Scholar
  • 8 Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016; 15: 51-69
    CrossrefPubMedGoogle Scholar
  • 9 Domouzoglou EM, Naka KK, Vlahos AP, Papafaklis MI, Michalis LK, Tsatsoulis A, Maratos-Flier E. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol 2015; 309: H1029-H1038
    CrossrefPubMedGoogle Scholar
  • 10 Zhang F, Yu L, Lin X, Cheng P, He L, Li X, Lu X, Tan Y, Yang H, Cai L, Zhang C. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Mol Endocrinol 2015; 29: 1400-1413
    CrossrefPubMedGoogle Scholar
  • 11 Nishimura T, Utsunomiya Y, Hoshikawa M, Ohuchi H, Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999; 1444: 148-151
    CrossrefPubMedGoogle Scholar
  • 12 Jahn D, Rau M, Hermanns HM, Geier A. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev 2015; 26: 625-635
    CrossrefPubMedGoogle Scholar
  • 13 Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225
    CrossrefPubMedGoogle Scholar
  • 14 Wistuba W, Gnewuch C, Liebisch G, Schmitz G, Langmann T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol 2007; 13: 4230-4235
    CrossrefPubMedGoogle Scholar
  • 15 Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA, Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010; 285: 14486-14494
    CrossrefPubMedGoogle Scholar
  • 16 Henkel AS, Anderson KA, Dewey AM, Kavesh MH, Green RM. A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB/NJ mice. J Lipid Res 2011; 52: 289-298
    CrossrefPubMedGoogle Scholar
  • 17 Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-1591
    CrossrefPubMedGoogle Scholar
  • 18 Straub L, Wolfrum C. FGF21, energy expenditure and weight loss - How much brown fat do you need?. Mol Metab 2015; 4: 605-609
    CrossrefPubMedGoogle Scholar
  • 19 Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. Tissue-specific expression of beta-Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687-26695
    CrossrefPubMedGoogle Scholar
  • 20 Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285: 5165-5170
    CrossrefPubMedGoogle Scholar
  • 21 Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. Nuclear receptors HNF4alpha and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem 2012; 287: 41334-41341
    CrossrefPubMedGoogle Scholar
  • 22 Li S, Hsu DD, Li B, Luo X, Alderson N, Qiao L, Ma L, Zhu HH, He Z, Suino-Powell K, Ji K, Li J, Shao J, Xu HE, Li T, Feng GS. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab 2014; 20: 320-332
    CrossrefPubMedGoogle Scholar
  • 23 Yu C, Wang F, Jin C, Huang X, McKeehan WL. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 2005; 280: 17707-17714
    CrossrefPubMedGoogle Scholar
  • 24 Shimizu M, Li J, Maruyama R, Inoue J, Sato R. FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress. Biochem J 2013; 450: 221-229
    CrossrefPubMedGoogle Scholar
  • 25 Miyata M, Hata T, Yamazoe Y, Yoshinari K. SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells. Biochem Biophys Res Commun 2014; 443: 477-482
    CrossrefPubMedGoogle Scholar
  • 26 Vergnes L, Lee JM, Chin RG, Auwerx J, Reue K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab 2013; 17: 916-928
    CrossrefPubMedGoogle Scholar
  • 27 Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2017; 282: 27277-27284
    PubMedGoogle Scholar
  • 28 Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-1624
    CrossrefPubMedGoogle Scholar
  • 29 Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, Ogimoto K, Schwartz MW. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010; 59: 1817-1824
    CrossrefPubMedGoogle Scholar
  • 30 Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Commun 2015; 6: 6980
    CrossrefPubMedGoogle Scholar
  • 31 Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-1747
    CrossrefPubMedGoogle Scholar
  • 32 Bhatnagar S, Damron HA, Hillgartner FE. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009; 284: 10023-10033
    CrossrefPubMedGoogle Scholar
  • 33 Miyata M, Sakaida Y, Matsuzawa H, Yoshinari K, Yamazoe Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol Pharm Bull 2011; 34: 1885-1889
    CrossrefPubMedGoogle Scholar
  • 34 Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 21: 203-206
    PubMedGoogle Scholar
  • 35 Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-443
    CrossrefPubMedGoogle Scholar
  • 36 Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, Lee H, Catana C, Klibanski A, Patwari P, Steinhauser ML. FGF21 and the late adaptive response to starvation in humans. J Clin Invest 2015; 125: 4601-4611
    CrossrefPubMedGoogle Scholar
  • 37 Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-425
    CrossrefPubMedGoogle Scholar
  • 38 Cyphert HA, Ge X, Kohan AB, Salati LM, Zhang Y, Hillgartner FB. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem 2012; 287: 25123-25133
    CrossrefPubMedGoogle Scholar
  • 39 Iizuka K, Takeda J, Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett 2009; 583: 2882-2886
    CrossrefPubMedGoogle Scholar
  • 40 Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA, Burgess SC. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009; 106: 10853-10858
    CrossrefPubMedGoogle Scholar
  • 41 Wang Y, Solt LA, Burris TP. Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor alpha. J Biol Chem 2010; 285: 15668-15673
    CrossrefPubMedGoogle Scholar
  • 42 Estall JL, Ruas JL, Choi CS, Laznik D, Badman M, Maratos-Flier E, Shulman GI, Spiegelman BM. PGC-1alpha negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb(alpha) axis. Proc Natl Acad Sci USA 2009; 106: 22510-22515
    CrossrefPubMedGoogle Scholar
  • 43 Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008; 28: 188-200
    CrossrefPubMedGoogle Scholar
  • 44 Li H, Gao Z, Zhang J, Ye X, Xu A, Ye J, Jia W. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 2012; 61: 797-806
    PubMedGoogle Scholar
  • 45 Nygaard EB, Vienberg SG, Orskov C, Hansen HS, Andersen B. Metformin stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res 2012; 15: 465282
    PubMedGoogle Scholar
  • 46 Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012; 148: 556-567
    CrossrefPubMedGoogle Scholar
  • 47 Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 2008; 74: 403-412
    CrossrefPubMedGoogle Scholar
  • 48 Oishi K, Tomita T. Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol Pharm Bull 2011; 34: 1120-1121
    CrossrefPubMedGoogle Scholar
  • 49 Luo Y, McKeehan WL. Stressed Liver and Muscle Call on Adipocytes with FGF21. Front Endocrinol 2013; 4: 00194
    PubMedGoogle Scholar
  • 50 Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M, Kuro-o M. Beta Klotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 2007; 104: 7432-7437
    CrossrefPubMedGoogle Scholar
  • 51 Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 2012; 7: 19-22
    PubMedGoogle Scholar
  • 52 Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, Möhlig M, Weickert MO, Clemenz M, Pfeiffer AF, Kintscher U, Spuler S, Spranger J. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009; 58: 1532-1538
    CrossrefPubMedGoogle Scholar
  • 53 Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, Kharitonenkov A, Spiegelman BM, Maratos-Flier E. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011; 152: 2996-3004
    CrossrefPubMedGoogle Scholar
  • 54 Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001; 413: 131-138
    CrossrefPubMedGoogle Scholar
  • 55 Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008; 8: 77-83
    CrossrefPubMedGoogle Scholar
  • 56 Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149: 6018-6027
    CrossrefPubMedGoogle Scholar
  • 57 Ishida N. Role of PPARalpha in the control of torpor through FGF21-NPY pathway: From circadian clock to seasonal change in mammals. PPAR Res 2009; 412949
    PubMedGoogle Scholar
  • 58 Zhang J, Gupte J, Gong Y, Weiszmann J, Zhang Y, Jeong Lee K, Richards WG, Li Y. Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action. EBioMedicine 2017; 15: 173-183
    CrossrefPubMedGoogle Scholar
  • 59 Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, Itoh N, Wang Y, Bornstein SR, Xu A, Li X. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013; 17: 779-789
    CrossrefPubMedGoogle Scholar
  • 60 Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007; 28: 2382-2386
    CrossrefPubMedGoogle Scholar
  • 61 Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, Ding X, Elmquist JK, Takahashi JS, Mangelsdorf DJ, Kliewer SA. FGF21 regulates circadian behavior and metabolism by acting on the nervous system. Nat Med 2013; 19: 1147-1152
    CrossrefPubMedGoogle Scholar
  • 62 Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, Kliewer SA, Mangelsdorf DJ. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 2014; 20: 670-677
    CrossrefPubMedGoogle Scholar
  • 63 Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635
    CrossrefPubMedGoogle Scholar
  • 64 Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55: 2470-2478
    CrossrefPubMedGoogle Scholar
  • 65 Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2010; 414: 788-791
    PubMedGoogle Scholar
  • 66 Wang C, Yang C, Chang JY, You P, Li Y, Jin C, Luo Y, Li X, McKeehan WL, Wang F. Hepatocyte FRS2alpha is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity. Curr Mol Med 2014; 14: 703-711
    CrossrefPubMedGoogle Scholar
  • 67 Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 2007; 210: 1-6
    CrossrefPubMedGoogle Scholar
  • 68 Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, Wu M, Sarr T, Zhu L, Guo H, Li Z, Li W, Hu W, Jiang G, Paweletz CP, Hendrickson RC, Thompson JR, Mu J, Berger JP, Mehmet H. Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One 2013; 8
    PubMed
  • 69 Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci 2010; 107: 12553-12555
    CrossrefPubMedGoogle Scholar
  • 70 Crowley VE, Yeo GS, O'Rahilly S. Obesity therapy: altering the energy intake-and-expenditure balance sheet. Nat Rev Drug Discov 2002; 1: 276-286
    CrossrefPubMedGoogle Scholar
  • 71 Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med 2011; 17: 736-740
    CrossrefPubMedGoogle Scholar
  • 72 Samms RJ, Smith DP, Cheng CC, Antonellis PP, Perfield JW, Kharitonenkov A, Gimeno RE, Adams AC. Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1. Cell Rep 2015; 11: 991-999
    CrossrefPubMedGoogle Scholar
  • 73 Véniant MM, Sivits G, Helmering J, Komorowski R, Lee J, Fan W, Moyer C, Lloyd DJ. Pharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue. Cell Metab 2015; 21: 731-738
    CrossrefPubMedGoogle Scholar
  • 74 Hao Y, Zhou J, Zhou M, Ma X, Lu Z, Gao M, Pan X, Tang J, Bao Y, Jia W. Serum levels of fibroblast growth factor 19 are inversely associated with coronary artery disease in chinese individuals. PLoS One 2013; 8: e72345
    CrossrefPubMedGoogle Scholar
  • 75 Reiche M, Bachmann A, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 2010; 42: 178-181
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49: 1228-1235
    CrossrefPubMedGoogle Scholar
  • 77 Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, Drápalová J, Hanušová V, Haluzík M. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol Re 2011; 60: 627-636
    PubMedGoogle Scholar
  • 78 Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298: G440-G445
    CrossrefPubMedGoogle Scholar
  • 79 Walters JR, Appleby RN. A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism. Ann Transl Med 2015; 3 (Suppl. 01) S7
    PubMedGoogle Scholar
  • 80 Chow WS, Xu A, Woo YC. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 2454-2455
    CrossrefPubMedGoogle Scholar
  • 81 Dostálová I, Kaválková P, Haluzíková D, Lacinová Z, Mráz M, Papezová H, Haluzík M. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J. Clin. Endocrinol. Metab 2008; 93: 3627-3632
    CrossrefPubMedGoogle Scholar
  • 82 Ling L, Lindhout DA. 2015. United States Patent No. US9089525 B1
    PubMed
  • 83 Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T, Learned RM, DePaoli AM, Tian H, Ling L. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res 2014; 74: 3306-3316
    CrossrefPubMedGoogle Scholar
  • 84 Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, To C, Learned RM, Tian H, DePaoli AM, Ling L. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014; 6: 3009098
    PubMedGoogle Scholar
  • 85 Alisi A, Ceccarelli S, Panera N, Prono F, Petrini S, De Stefanis C, Pezzullo M, Tozzi A, Villani A, Bedogni G, Nobili V. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS One 2013; 8: 1-6
    CrossrefPubMedGoogle Scholar
  • 86 Zhang X, Hu Y, Zeng H, Li L, Zhao J, Zhao J, Liu F, Bao Y, Jia W. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol 2015; 14: 015-0190
    CrossrefPubMedGoogle Scholar
  • 87 Das TK, Hodge TS, Ishino T, Levin NJ, Sitharamaiah M, Palanki S, Parsons EK, Violand BN. United States Patent No. US 8,722,622 B2; 2014;
    PubMed
  • 88 Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract 2014; 21:
    PubMed
  • 89 Keller KB, Lemberg L. Obesity and the metabolic syndrome. Am J Crit Care 2003; 12: 167-170
    PubMedGoogle Scholar
  • 90 World Health Organization. Fact Sheet. Obesity and overweight 2016
    PubMed
  • 91 Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: A review. World J Diabetes 2010; 1: 76-88
    CrossrefPubMedGoogle Scholar
  • 92 Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, Domingo P, Giralt M, Frühbeck G, Villarroya F. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes 2015; 39: 121-129
    CrossrefPubMedGoogle Scholar
  • 93 Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, Rodríguez A, Domingo P, Moncada R, Valentí V, Salvador J, Giralt M, Villarroya F, Frühbeck G. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr 2017; 36: 861-868
    CrossrefPubMedGoogle Scholar
  • 94 Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-2603
    CrossrefPubMedGoogle Scholar
  • 95 Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013; 154: 9-15
    CrossrefPubMedGoogle Scholar
  • 96 Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, Bergman RN, Wasserman DH, Schwartz MW. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 2013; 123: 4799-4808
    CrossrefPubMedGoogle Scholar
  • 97 Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, Kabaroglu C, Ozmen D, Mutaf I, Bayindir O. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011; 41: 390-398
    PubMedGoogle Scholar
  • 98 Marcelin G, Jo YH, Li X, Schwartz GJ, Zhang Y, Dun NJ, Lyu RM, Blouet C, Chang JK, Chua Jr. S. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 2013; 3: 19-28
    PubMedGoogle Scholar
  • 99 Fu T, Choi SE, Kim DH, Seok S, Suino-Powell KM, Xu HE, Kemper JK. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc Natl Acad Sci U S A 2012; 109: 16137-16142
    CrossrefPubMedGoogle Scholar
  • 100 Wu X, Ge H, Baribault H, Gupte J, Weiszmann J, Lemon B, Gardner J, Fordstrom P, Tang J, Zhou M, Wang M, Li Y. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res 2013; 54: 325-332
    CrossrefPubMedGoogle Scholar
  • 101 Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160: 2295-2307
    CrossrefPubMedGoogle Scholar
  • 102 Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weiszmann J, Gupte J, Gardner J, Lindberg R, Wang Z, Li Y. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A 2010; 107: 14158-14163
    CrossrefPubMedGoogle Scholar
  • 103 Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789
    CrossrefPubMedGoogle Scholar
  • 104 Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012; 97: 2143-2150
    CrossrefPubMedGoogle Scholar
  • 105 Adams AC, Halstead CA, Hansen BC, Irizarry AR, Martin JA, Myers SR, Reynolds VL, Smith HW, Wroblewski VJ, Kharitonenkov A. LY2405319, an Engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 2013; 8: 1-6
    CrossrefPubMedGoogle Scholar
  • 106 Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2077 148: 774-781
    PubMedGoogle Scholar
  • 107 Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259
    CrossrefPubMedGoogle Scholar
  • 108 Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, Mohammadi M, Potthoff MJ. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014; 63: 4057-4063
    CrossrefPubMedGoogle Scholar
  • 109 Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, Serr J, Zhang D, Kahn M, Samuel VT, Jurczak MJ, Shulman GI. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 2013; 154: 3099-3109
    CrossrefPubMedGoogle Scholar
  • 110 Véniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, Busby J, Vonderfecht S, Xu J, Lloyd DJ. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 2012; 7: e40164
    CrossrefPubMedGoogle Scholar
  • 111 Asrih M, Veyrat-Durebex C, Poher AL, Lyautey J, Rohner-Jeanrenaud F, Jornayvaz FR. Leptin as a potential regulator of FGF21. Cell Physiol Biochem 2016; 38: 1218-1225
    CrossrefPubMedGoogle Scholar
  • 112 Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, Dallas-Yang Q, Putnam AM, Yao J, Bussell S, Wu M, Norman TC, Rodriguez CG, Kimmel B, Metzger JM, Manibusan A, Lee D, Zaller DM, Zhang BB, DiMarchi RD, Berger JP, Axelrod DW. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012; 61: 505-512
    CrossrefPubMedGoogle Scholar
  • 113 Ye X, Qi J, Yu D, Wu Y, Zhu S, Li S, Wu Q, Ren G, Li D. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. J Diabetes Complicat 2017; 31: 726-734
    CrossrefPubMedGoogle Scholar
  • 114 Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders. Front Endocrinol 2015; 6: 168
    PubMedGoogle Scholar
  • 115 Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18: 333-340
    CrossrefPubMedGoogle Scholar
  • 116 Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther 2013; 346: 270-280
    CrossrefPubMedGoogle Scholar
  • 117 Weng Y, Chabot JR, Bernardo B, Yan Q, Zhu Y, Brenner MB, Vage C, Logan A, Calle R, Talukdar S. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS One 2015; 10: e0119104
    CrossrefPubMedGoogle Scholar
  • 118 Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, Calle RA. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metab 2016; 23: 427-440
    CrossrefPubMedGoogle Scholar
  • 119 Thompson WC, Zhou Y, Talukdar S, Musante CJ. PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. J Pharmacokinet Pharmacodyn 2015; 43: 411-425
    PubMedGoogle Scholar
  • 120 Dong JQ, Rossulek M, Somayaji VR, Baltrukonis D, Liang Y, Hudson K, Hernandez-Illas M, Calle RA. Pharmacokinetics, and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br J Clin Pharmacol 2015; 80: 1051-1063
    CrossrefPubMedGoogle Scholar
  • 121 Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C, Tam LT, Shen Z, Stanislaus S, Chinookoswong N, Lau Y, Sickmier A, Michaels ML, Boone T, Véniant MM, Xu J. Rationale-based engineering of a potent long-acting fgf21 analog for the treatment of type 2 diabetes. PLoS One 2012; 7: 27
    PubMedGoogle Scholar
  • 122 Ye XL, Gao HS, Wang WF, Ren GP, Liu MY, He K, Zhang YK, Zhao JZ, Yu D, Li DS. Optimization and characterization of a novel FGF21 mutant. Yao Xue Xue Bao 2012; 47: 897-903
    PubMedGoogle Scholar
  • 123 Chechi K, Nedergaard J, Richard D. Brown adipose tissue as an anti-obesity tissue in humans. Obes Rev 2014; 15: 92-106
    CrossrefPubMedGoogle Scholar
  • 124 Kim SH, Plutzky J. Brown Fat, and Browning for the Treatment of Obesity and Related Metabolic Disorders. Diabetes Metab J 2016; 40: 12-21
    CrossrefPubMedGoogle Scholar
  • 125 Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Kharitonenkov A, Flier JS, Maratos-Flier E, Spiegelman BM. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012; 26: 271-281
    CrossrefPubMedGoogle Scholar
  • 126 Oh KJ, Lee DS, Kim WK, Han BS, Lee SC, Bae KH. Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int J Mol Sci 2017; 18: 2-31
    PubMedGoogle Scholar